摘要
目的探讨利培酮对非酶抗氧化物浓度的影响。方法纳入首发精神分裂症患者161例,接受10周单一利培酮治疗,138例患者完成研究。另设与患者年龄、性别、受教育程度相匹配的正常对照42名。采用阳性和阴性症状量表(positive and negative syndrome scale,PANSS)评估患者精神症状;治疗前后检测患者血清白蛋白、胆红素、尿酸浓度,对照组仅检测一次。结果治疗前患者组白蛋白、尿酸浓度低于对照组,患者组直接胆红素浓度高于对照组,间接胆红素浓度低于对照组(均P<0.05)。与治疗前比较,治疗后患者尿酸、总胆红素、直接胆红素、间接胆红素浓度下降(均P<0.05),且PANSS总分降低(P<0.05)。多因素线性回归分析显示,患者PANSS总分改善值与治疗前尿酸浓度相关联(β=0.27,P<0.01)。结论利培酮可引起首发精神分裂症患者非酶抗氧化物浓度下降,某些抗氧化物浓度可能与临床疗效存在关联。
ObjectiveTo explore the effect of resperidone treatment on serum levels of nonenzymatic antioxidant in drug-na？ve first-episode schizophrenic patients.MethodsOne hundred and sixty one schizophrenic patients and forty two normal controls matched for sex and education were recruited. The patients were treated with risperidone. Positive and negative syndrome scale（PANSS） were used to estimate the clinical effects. Serum albumin, bilirubin and uric acid levels were detected in the patients before and after 10-week treatment with risperidone and in normal controls. One hundred and thirty eight patients with schizophrenia had finished the study.ResultsAlbumin and once uric acid levels were significantly lower in patients compared to the controls（all P〈0.05）. Direct bilirubin levels was higher in patients than in the controls（P〈0.05）. Indirect bilirubin level in patients was lower comparing to the normal controls（P〈0.05）. Uric acid,total bilirubin, direct and indirect bilirubin levels were significantly decreased after treatment（all P〈0.05）. The reduction in the PANSS total score from baseline to week 10 were associated with uric acid at baseline（β=0.27, P0.01）.ConclusionsReperidone may decrease nonenzymatic antioxidant levels in first-episode schizophrenic patients. Some antioxidant levels at pre-treatment may be associated with improvement of psychopathological symptoms.
出处
《中国神经精神疾病杂志》
CAS
CSCD
北大核心
2015年第9期518-522,共5页
Chinese Journal of Nervous and Mental Diseases
基金
美国国立精神卫生研究所(NIMH)资助项目(编号:H-22473)
关键词
精神分裂症
抗氧化剂
自由基
First-episode schizophrenia
Antioxidant
Free radicals
